drugset / Trial / NCT04114292

TUDCA as a Therapy for Ulcerative Colitis (UC)

NCT04114292 ↗

NaSingle-groupOpen-labelHealth-services research

Summary

This is a Phase I open label study examining the efficacy and safety of TUDCA (tauroursodeoxycholic acid) in ulcerative colitis treatment.

Timeline

Start
2019-01-17
Primary completion
2022-06-07
Completion
2022-06-07

Outcome

Met primary endpoint

paper Mucosal biopsies revealed significant reductions in ER stress and inflammation as well as an increase in markers of epithelial restitution. PMID 40236400 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Taurursodiol Small molecule 1.75 g Oral
Subject Taurursodiol Small molecule 2 g Oral

Indications